This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardialinfarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidneydisease (CKD), and cardiovascular risk factors, a prespecified.
Significant complications associated with this condition include ischemic stroke, heart failure, myocardialinfarction, chronic kidneydisease, dementia and mortality. In the U.S.,
Myocardialinfarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidneydisease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
Data on major cardiovascular events (MACE; mortality, myocardialinfarction, stroke, heart failure) through December 2021 were obtained from national registries. Results Among all patients (n = 38,671), 31% had stable CAD, and 69% suffered an acute myocardialinfarction. vs. 67.1%) than other GLD.
BackgroundThis realworld evidence study compared risks of cardiovascular events in hospital settings among patients with chronic kidneydisease (CKD) with and without hyperkalemia.Methods and ResultsAdults with CKD stages 3b/4 with and without hyperkalemia were identified from Optum's deidentified Market Clarity Data (January 2016August 2022).
Efficacy and safety of finerenone in patients with chronic kidneydisease and type 2 diabetes by diuretic use: a FIDELITY analysis. b Composite of time to CV death, non-fatal MI, non-fatal stroke, or HHF. d Composite of time to kidney failure, sustained 57% decrease in eGFR from baseline over 4weeks, or kidney-related death.
Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidneydisease and heart failure. Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024.
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 Studies have shown that people with A-Fib are up to 5 times more likely to have a stroke. tim.hodson Wed, 09/11/2024 - 15:40 Sept.
Study end points include mortality, cardiovascular events (hospitalization for acute myocardialinfarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%
Stroke, Volume 56, Issue Suppl_1 , Page AWP289-AWP289, February 1, 2025. Background:The ABCD-GENE score, incorporating age, body mass index, chronic kidneydisease, diabetes, and CYP2C19 genotypes, is a validated risk score that integrates clinical risk factors with genetic information to predict clopidogrel response.
Objective Risk-guided atrial fibrillation (AF) screening may be an opportunity to prevent adverse events in addition to stroke. We compared events rates for new diagnoses of cardio-renal-metabolic diseases and death in individuals identified at higher versus lower-predicted AF risk. to 8.34; 4.27), myocardialinfarction (69.6;
615 patients, the 186 (30.2%) patients with protruding aortic plaque were older and had more comorbidities such as hypertension, chronic kidneydisease, and a prior myocardialinfarction than those without.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 Studies have shown that people with A-Fib are up to 5 times more likely to have a stroke. tim.hodson Wed, 09/11/2024 - 15:40 Sept.
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among Results:Among 5002 (projected to 34.0
BACKGROUND:Advanced chronic kidneydisease is associated with high cardiovascular risk, even after kidney transplant. METHODS:We retrospectively followed patients who underwent MPI before kidney transplant for the occurrence of MACE after transplant including myocardialinfarction, stroke, heart failure, and cardiac death.
17] Glycemic improvement alone, however, has not been associated with improved risk of macrovascular diabetes complications, such as myocardialinfarction, stroke and heart failure.
AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardialinfarction, sudden cardiac death, heart failure (HF), chronic kidneydisease (CKD), and peripheral artery disease (PAD). million.
BackgroundPatients with both acute coronary syndrome (ACS) and chronic kidneydisease (CKD) face heightened risks of adverse cardiovascular events and bleeding. No significant differences were observed in all-cause mortality, major bleeding, cardiovascular death, or acute myocardialinfarction.
The eGFR estimates were calculated using the Chronic KidneyDisease Epidemiology Collaboration (CKD-EPI) equation. CVD was defined as a self-reported physician's diagnosis of congestive heart failure, coronary heart disease, angina pectoris, myocardialinfarction, or stroke. ml/min/1.73 m².
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content